HUP0400530A2 - A1 adenozin receptor antagonista hatású kondenzált purinszármazékok - Google Patents

A1 adenozin receptor antagonista hatású kondenzált purinszármazékok

Info

Publication number
HUP0400530A2
HUP0400530A2 HU0400530A HUP0400530A HUP0400530A2 HU P0400530 A2 HUP0400530 A2 HU P0400530A2 HU 0400530 A HU0400530 A HU 0400530A HU P0400530 A HUP0400530 A HU P0400530A HU P0400530 A2 HUP0400530 A2 HU P0400530A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
substituted
hydrogen atom
optionally substituted
Prior art date
Application number
HU0400530A
Other languages
English (en)
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP0400530A2 publication Critical patent/HUP0400530A2/hu
Publication of HUP0400530A3 publication Critical patent/HUP0400530A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány (I) és (II) általános képletű vegyületekre vonatkozik - aképletben R1 és R2 jelentése egymástól függetlenül a) hidrogénatom, b) adott esetben szubsztituált alkil-, alkenil-vagy alkinilcsoport, vagy c) aril- vagy szubsztituált arilcsoport; R3jelentése egy adott esetben szubsztituált biciklusos, triciklusos vagypentaciklusos csoport: R4 jelentése hidrogénatom, adott esetbenszubsztituált 1-4 szénatomos alkil-, 1-4 szénatomos alkil-CO2H vagyfenilcsoport, R5 jelentése: -(CR1R2)nCOOH, -C(CF3)20H, -CONHNHSO2CF3,-CONHOR4, -CONHSO2R4, -CONHSO2NHR4, -C(OH)R4PO3H2, -NHCOCF3, -NHCONHSO2R4, -NHPO3H2, -NHSO2R4, -NHSO2NHCOR4, -OPO3H2, -OSO3H, -PO(OH)R4, -PO3H2, -SO3H, -SO2NHR4, -SO3NHCOR4, -SO3NHCONHCO2R4 vagy nértéke 0, 1, 2 vagy 3, A jelentése valamely következő csoport: -CH=CH,-(CH)m-(CH)m, CH=CH-CH2 vagy -CH2-CH=CH; m értéke 1 vagy 2; Xjelentése O vagy S, Z jelentése egyeskötés, -O-, -(CH2)n-, -O(CH2)1,2-, -CH2OCH2-, -(CH2)1-2O-, és R6 jelentése hidrogénatom-,alkil-, acil-, alkilszulfonil-, aralkil-, szubsztituált aralkil-,szubsztituált alkil- vagy heterociklusos-csoport; és R7 jelentése: a)hidrogénatom; b) adott esetben szubsztituált alkil-, nem kevesebb,mint 3 szénatomot tartalmazó alkenil- vagy nem kevesebb, mint 3szénatomot tartalmazó alkinilcsoport; c) aril- vagy szubsztituáltarilcsoport; d) alkilaril- vagy arilcsoporttal szubsztituáltalkilcsoport. A fenti (I) általános képletű vegyületek A1 adenozinreceptor antagonista hatásúak. A találmány vonatkozik továbbá a fentivegyületeket tartalmazó gyógyszerkészítményekre. Ó
HU0400530A 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists HUP0400530A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0400530A2 true HUP0400530A2 (hu) 2004-06-28
HUP0400530A3 HUP0400530A3 (en) 2007-05-29

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400530A HUP0400530A3 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Country Status (33)

Country Link
US (2) US6605601B2 (hu)
EP (1) EP1347981B1 (hu)
JP (2) JP2004514723A (hu)
KR (1) KR20040011439A (hu)
CN (1) CN100497340C (hu)
AR (1) AR035400A1 (hu)
AT (1) ATE394402T1 (hu)
AU (2) AU1997702A (hu)
BG (1) BG107849A (hu)
BR (1) BR0115833A (hu)
CA (1) CA2430508C (hu)
CZ (1) CZ20031513A3 (hu)
DE (1) DE60133931D1 (hu)
EA (1) EA009814B1 (hu)
EE (1) EE200300260A (hu)
ES (1) ES2305139T3 (hu)
GE (1) GEP20094697B (hu)
HK (1) HK1059927A1 (hu)
HU (1) HUP0400530A3 (hu)
IL (1) IL156046A0 (hu)
IS (1) IS6821A (hu)
MX (1) MXPA03004857A (hu)
MY (1) MY127120A (hu)
NO (1) NO20032483L (hu)
NZ (1) NZ526511A (hu)
PL (1) PL362642A1 (hu)
SK (1) SK6552003A3 (hu)
TR (1) TR200300766T2 (hu)
TW (1) TWI293301B (hu)
UA (1) UA75625C2 (hu)
WO (1) WO2002044182A1 (hu)
YU (1) YU42903A (hu)
ZA (2) ZA200304067B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522971A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
CA2523763A1 (en) * 2003-04-25 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivative
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
EP1863815A1 (en) * 2005-03-11 2007-12-12 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
WO2007117549A2 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2431368B1 (en) 2006-05-19 2014-08-27 AbbVie Bahamas Ltd. CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
WO2007150026A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
KR20200106176A (ko) 2018-01-04 2020-09-11 임페티스 바이오사이언시즈 엘티디. 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
ATE258171T1 (de) 1991-09-23 2004-02-15 Univ Florida State Metallalkoxide
CA2239881A1 (en) * 1996-10-07 1998-04-16 Nobuo Kosaka Condensed purine derivatives
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
ES2284256T3 (es) 1998-07-02 2007-11-01 Kyowa Hakko Kogyo Co., Ltd. Medicamentos para la diabetes.
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru

Also Published As

Publication number Publication date
KR20040011439A (ko) 2004-02-05
CZ20031513A3 (cs) 2003-09-17
UA75625C2 (en) 2006-05-15
TWI293301B (en) 2008-02-11
AR035400A1 (es) 2004-05-26
HUP0400530A3 (en) 2007-05-29
US6605601B2 (en) 2003-08-12
EP1347981A1 (en) 2003-10-01
US20020111333A1 (en) 2002-08-15
BR0115833A (pt) 2003-10-28
IS6821A (is) 2003-05-20
PL362642A1 (en) 2004-11-02
ES2305139T3 (es) 2008-11-01
NO20032483L (no) 2003-07-30
CN1481387A (zh) 2004-03-10
YU42903A (sh) 2006-05-25
DE60133931D1 (de) 2008-06-19
EP1347981B1 (en) 2008-05-07
MXPA03004857A (es) 2003-08-19
WO2002044182A1 (en) 2002-06-06
NZ526511A (en) 2005-04-29
SK6552003A3 (en) 2003-12-02
CA2430508C (en) 2010-05-18
GEP20094697B (en) 2009-06-10
AU2002219977B2 (en) 2008-01-24
EE200300260A (et) 2003-08-15
IL156046A0 (en) 2003-12-23
ZA200408755B (en) 2005-07-27
CA2430508A1 (en) 2002-06-06
MY127120A (en) 2006-11-30
BG107849A (bg) 2004-01-30
HK1059927A1 (en) 2004-07-23
US7022686B2 (en) 2006-04-04
NO20032483D0 (no) 2003-06-02
EA200300629A1 (ru) 2003-12-25
AU1997702A (en) 2002-06-11
CN100497340C (zh) 2009-06-10
JP2004514723A (ja) 2004-05-20
JP2010053148A (ja) 2010-03-11
ZA200304067B (en) 2005-05-30
EA009814B1 (ru) 2008-04-28
ATE394402T1 (de) 2008-05-15
US20030220358A1 (en) 2003-11-27
TR200300766T2 (tr) 2004-09-21

Similar Documents

Publication Publication Date Title
HUP0400530A2 (hu) A1 adenozin receptor antagonista hatású kondenzált purinszármazékok
HUP0302962A2 (hu) Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása
HUP9802300A2 (hu) N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9701269A2 (hu) Abszorbens készítmény savas komponenseket tartalmazó gázok tisztítására
HUP0203483A2 (hu) Purinszármazékok
EP1070710A3 (en) Dithiolan derivatives, their preparation and their therapeutic effect
HUP0100889A2 (hu) Tumorellenes hatású 6,9-diszubsztituált, 2-{transz-(4-amino-ciklohexil)-amino}-purinok és azokat tartalmazó gyógyszerkészítmények
HUP9903971A1 (hu) Izoflavonok alkalmazása klimax elleni gyógyszerkészítmények előállítására
DE3853477D1 (de) Makrozyklische verbindungen.
HUP0001494A2 (hu) 3-Fenoxi-, 3-dibenzo[a,d]cikloheptenil-oxi-, 3-dibenz[b,f]-[1,4]oxazepinil-oxi-1-amino-2-propanol-származékok és az ezeket tartalmazó gyógyszerkészítmények
OA09468A (fr) Nouveaux dérivés du 1,2-benzisoxazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
DK0409406T3 (da) Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
ATE250623T1 (de) 4'-c-ethynyl-purin-nukleoside
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
FI942944A0 (fi) Uusia 19-nor-steroideja, joilla on asemassa 11beta tiohiiliketju, menetelmä niiden valmistamiseksi ja tämän menetelmän välituotteita, niiden käyttö lääkkeinä ja koostumuksia
ES8301881A1 (es) Un procedimiento para la preparacion de derivados de ariletanolamina que tienen actividad antiobesidad yno hploglicemi- ca.
HUP0002311A2 (hu) Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk
ATE73780T1 (de) Glutaminsaeure-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische formulierungen.
SE9904129D0 (sv) Novel compounds
FI922983A (fi) Pyrimidin-4-karboxamidderivat, framstaellning av dessa och terapeutisk anvaendning av dessa
ATE266664T1 (de) Pyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
HUP0203471A2 (hu) Trombózisellenes hatású vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO4990965A1 (es) Derivados de 1,3,8-triazaspiro(4,5)decan-4-ona to que los contiene y un proceso para la preparacion de es- tos derivados

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees